Osteoprotegerin, Rank, Rankl

Stejskal, David; Bartek, Jiri; Pastorková, R; Růžička, Viktor; Oral, I; Horalík, D

doi:10.5507/bp.2001.013

Cited by 36 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RANKL binds to RANK on the surface of preosteoclasts and stimulates the development and activation of osteoclasts. OPG, also known as tumour necrosis factor receptor superfamily member 11B (TNFRSF11B), is secreted by many cell types, in addition to osteoblasts, including heart, kidney, liver, and spleen [2,3]. OPG is a soluble decoy receptor for RANKL that inhibits the proosteoclastogenic interaction between RANKL and RANK, thereby inhibiting bone resorption [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

The Role of RANK/RANKL/OPG Signalling Pathways in Osteoclastogenesis in Odontogenic Keratocysts, Radicular Cysts, and Ameloblastomas

Tekkeşın

Mutlu

Olgaç

2011

Head and Neck Pathol

View full text Add to dashboard Cite

The aim of this study was to evaluate the immunohistochemical expression of molecules involved in osteoclastogenesis, including the receptor activator of nuclear factor kappa B (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in odontogenic keratocysts (OKCs), which has been named as a keratocystic odontogenic tumour by the WHO, and compare their expression with radicular cysts and ameloblastomas. RANK is a member of tumour necrosis factor receptor family and it is activated by RANK ligand. OPG binds to RANKL and inactivates it. The imbalance of these factors could cause the differential bone resorption activity in some diseases and tumours. The expression of these molecules was evaluated in ameloblastomas (n = 20), OKCs (n = 20), and radicular cysts (n = 20) by immunohistochemistry. Immunohistochemical reactivity for RANK, RANKL, and OPG was detected in neoplastic and nonneoplastic epithelium and connective tissue cells. RANK showed the greatest expression in OKCs followed by ameloblastomas, with the lowest expression seen in radicular cysts. Expression of RANKL was detected in all lesions and no significant differences were observed between groups. OPG was expressed very low in all groups. In the stroma, the number of RANK positive cells was higher in OKCs when compared with ameloblastomas and radicular cysts but radicular cyst had higher numbers of RANKL positive cells in the stroma than ameloblastomas. The molecular system of RANK/RANKL/OPG is variably expressed in OKCs, radicular cysts, and ameloblastomas and this system may be involved in the osteoclastogenic mechanisms in OKCs and ameloblastomas. Advanced studies could further clarify the role of RANK, RANKL, and OPG in mediating tumour associated bone osteolysis.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of RANK/RANKL/OPG Signalling Pathways in Osteoclastogenesis in Odontogenic Keratocysts, Radicular Cysts, and Ameloblastomas

Tekkeşın

Mutlu

Olgaç

2011

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…Этот про-цесс контролируется системой из 3 ключевых белков: RANK, RANKL и «приманивающего» рецептора OPG [3].…”

Section: Introductionunclassified

Osteoprotegerin as a Predictive Marker of the Course of Breast Cancer

Заброда¹,

Маслюкова²,

Корытова³

et al. 2015

Tumors of female reproductive system

View full text Add to dashboard Cite

“…OPG is a peptide member of the TNF receptor super-family that is synthesized by osteoblasts [62]. OPG is a free-floating, soluble decoy receptor that binds to RANKL and inhibits osteoclastgenesis and bone resorption [62]. Serum concentrations of OPG increase with age and may be a compensatory response to enhanced bone resorption in the estrogen deficient state or to age-dependent bone loss [63].…”

Section: Osteoprotegerin/rank/ranklmentioning

confidence: 99%

“…Serum concentrations of OPG increase with age and may be a compensatory response to enhanced bone resorption in the estrogen deficient state or to age-dependent bone loss [63]. Vitamin D 3 , PTH, prostaglandin E2 (PGE2), IL-1, IL-4, IL-6, IL-11, IL-17, and TNF-a all appear to stimulate osteoclastgenesis through the dual action of inhibiting production of OPG and stimulating production of RANKL [62,64]. Estrogens, on the other hand, appear to inhibit production of RANKL and RANKL-stimulated osteoclastgenesis [64].…”

Section: Osteoprotegerin/rank/ranklmentioning

confidence: 99%

“…This interaction leads to the differentiation and maturation of osteoclasts which coalesce and become capable of resorbing bone. OPG is a peptide member of the TNF receptor super-family that is synthesized by osteoblasts [62]. OPG is a free-floating, soluble decoy receptor that binds to RANKL and inhibits osteoclastgenesis and bone resorption [62].…”

Section: Osteoprotegerin/rank/ranklmentioning

confidence: 99%

See 1 more Smart Citation

Osteobiology of Aging

Rosenzweig¹,

Pignolo

2010

Fractures in the Elderly

View full text Add to dashboard Cite

The goals of this chapter will be to give a brief overview of bone biology, describe the molecular mechanisms of bone remodeling and pathologic uncoupling, and provide a general survey of the multiple pathways leading to aging bone and osteoporosis. Keywords IntroductionThe human skeleton is a dynamic organ that serves multiple functions including support, protection, storing metabolic building blocks, and providing insertion points for tendons and ligaments. A tightly coupled mechanism known as remodeling exists in the skeleton which allows for the constant turnover of bone, even after longitudinal growth has ceased. Osteoclasts reabsorb old bone and osteoblasts follow closely, laying down new structural units of bone. There is a complex interplay between these cells mediated by many endogenous local and systemic factors as well as exogenous mechanical stresses [1]. Peak bone mass usually occurs in the third decade of life in humans after which there is a period of relatively stable bone mass followed by progressive decline. As the body ages, the mechanism of bone remodeling becomes more dysfunctional, leading to an uncoupling of bone formation and resorption and a net loss of bone density and structural integrity, causing osteoporosis and increasing the risk of fractures.

show abstract

Osteoprotegerin, Rank, Rankl

Cited by 36 publications

References 35 publications

The Role of RANK/RANKL/OPG Signalling Pathways in Osteoclastogenesis in Odontogenic Keratocysts, Radicular Cysts, and Ameloblastomas

The Role of RANK/RANKL/OPG Signalling Pathways in Osteoclastogenesis in Odontogenic Keratocysts, Radicular Cysts, and Ameloblastomas

Osteoprotegerin as a Predictive Marker of the Course of Breast Cancer

Osteobiology of Aging

Contact Info

Product

Resources

About